Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Placebo- and Active-controlled, Parallel-group, 24-week Proof of Concept and Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Heart Failure

Next Previous
Trial Profile

A Multi-center, Randomized, Placebo- and Active-controlled, Parallel-group, 24-week Proof of Concept and Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Heart Failure

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XXB 750 (Primary) ; Sacubitril/valsartan
  • Indications Heart failure
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 28 Nov 2024 Status changed from active, no longer recruiting to discontinued.
  • 12 Sep 2024 Status changed from recruiting to active, no longer recruiting.
  • 26 Jan 2024 Planned End Date changed from 28 Jan 2026 to 22 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top